Navigation Links
Intimate Bridge 2 Conception, Inc. Receives $4.3M
Date:12/22/2011

PITTSBURGH, Dec. 22, 2011 /PRNewswire/ -- Intimate Bridge 2 Conception, Inc. (Ib2C™), a Pittsburgh-based direct-to-consumer medical device company that is focused on reproductive health, announced today that it has closed on a $4.3 million Series A financing.  The round was led by a private, Pennsylvania-based investment group and was joined by the PLSG Accelerator Fund.  Ib2C will use the proceeds of this round for manufacturing and marketing to prepare for the launch of its first product in 2012.

Ib2C™ is developing healthcare products to assist women and couples to achieve their reproductive goals.  Ib2C™'s lead product, the Stork™, is a proprietary device that is intended to assist couples with conception in the privacy of their own homes.  The Stork™ is designed to address the unmet need of a growing market of couples that grapple with fertility challenges.  It is a simple, private, affordable, non-pharmaceutical product that will provide couples with an alternative to Assisted Reproductive Technology (ART), which can involve invasive procedures, trips to physician offices, long delays, and can be both expensive and unpredictable. The Stork™ is currently being evaluated by the FDA for safety and effectiveness.  The technology behind the Stork™ has been shown historically to achieve results that are comparable to those of intrauterine insemination (IUI.)

"We are grateful for this capital from our new investors and appreciate their support for our mission to build families naturally," said Ib2C™'s Founder and CEO Steve Bollinger. "Today, one in six women seeks help conceiving. This segment of the population has very few options, most of which are slow, invasive, costly and frequently awkward. We are delighted to offer them an option that can deliver technology, hope and control in the privacy of their own home." Mr. Bollinger continues, "This financing will enable us to launch our first product and begin to help families in 2012."

"Our group believes strongly in supporting women and couples that cannot afford the more costly steps in assisted reproduction," said the lead investor in the Series A financing. "With medical technologies becoming less and less affordable to the average patient, we are pleased to support an affordable, drug-free solution, which can aid in the path to conception in the privacy of a couple's home."

"It is exciting that Ib2C has addressed this problem with a proven medical approach that has been used by physicians for years and created a device that can be used by average people around the world to nudge the stork," said John Manzetti, Managing Director of the PLSG Accelerator Fund. "Ib2C™ is a Pittsburgh Life Sciences Greenhouse portfolio company and a great example of a healthcare solution that has been nurtured at the PLSG Incubator. I am thrilled to watch this solution be launched from Pittsburgh."

About Ib2C and Founder & CEO Stephen Bollinger

Ib2C is a direct-to-consumer medical device company that is focused on reproductive health to aid in natural fertility and conception in the privacy of the patients' home. The Company's mission is to give women and couples healthcare products that will help them reach their reproductive goals, targeting two significant populations: individuals diagnosed with infertility who have not been able to afford, or achieve success with, existing alternative therapies; and fertile women who have a need or desire to delay insemination.   

Ib2C's lead technology, the Stork™, is a conception aid system that is designed to address the growing unmet need of delayed and/or unsuccessful natural fertility.  Historically, the technology used with the Stork™ has been shown to provide results similar to those associated with intrauterine insemination (IUI), and allows the procedure to be done in the privacy of the home. The Stork™ is a simple, private, non-pharmaceutical and economical method to help expedite and overcome many of the infertility issues of today's patient population.

Steve Bollinger brings a diverse background with respect to the medical device and biologic market place. He has held multiple leadership positions from a Founder, President and Chief Operations Officer, of early stage companies, to a broad spectrum of roles not limited to, global operations, marketing, product management and sales. He is currently an Executive-in-Residence at the Pittsburgh Life Sciences Greenhouse.

Mr. Bollinger currently holds seven medical patents, with multiple pending. He is a graduate of the United States Military Academy West Point with a BS in mechanical engineering. He has raised over $50 million over the last 10 plus years while delivering strong returns to his investors.

About the PLSG Accelerator Fund, LLC

The PLSG Accelerator Fund, LLC venture fund is a $10 million for-profit venture fund with an investment period of up to five years. The PLSG Accelerator Fund, LLC is designed to make early stage investments in life sciences companies located in western Pennsylvania.  The Accelerator Fund is managed by professionals on the Pittsburgh Life Sciences Greenhouse (PLSG) staff and will use the PLSG's deep knowledge of global industry trends, access to industry contacts nationwide and experience in corporate collaborations to identify worthy investment opportunities within western Pennsylvania from the portfolio of PLSG companies. The Accelerator Fund also makes co-investment in portfolio companies with other venture capital funds.


'/>"/>
SOURCE Pittsburgh Life Sciences Greenhouse
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
2. Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities
3. University of Muenster Bridges 1st Patient to Transplant with SynCardias Total Artificial Heart
4. Narrowest bridges of gold are also the strongest, study finds
5. Core Informatics Announces Second Office Location in Cambridge Massachusetts
6. Bacterin International Holdings Secures $5,000,000 Credit Facility with Bridge Bank
7. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
8. The iBridge Network Adds Torontos University Health Network as First Canadian Partner
9. Bioscience Bridge, LLC Launches as a Technology Transfer Agency for University-Based Bioscience Research
10. BioMed Realty Trust Expands Lease With Ironwood Pharmaceuticals for 50,000 Square Feet in Cambridge, Massachusetts
11. Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):